Art. -Nr.: HY-114409

GB1107

20 Cited Publications

Kundenbewertung

Based on 20 publication(s) in Google Scholar

GB1107 is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with a K_d of 37 nM for human Galectin-3. GB1107 reduces human and mouse lung adenocarcinoma growth and blocks metastasis in the syngeneic model.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.92%
CAS. Nr.: 1978336-61-6
Formel: C₂₀H₁₆Cl₂F₃N₃O₄S
Molecular Weight:522.32

Speicherung:

-20°C, stored under nitrogen

* In solvent : -80°C, 2 years; -20°C, 1 year (stored under nitrogen)

GB1107 Chemical Structure

CAS. Nr.: 1978336-61-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (20)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Galectin-3

Alle Galectin Isoform-spezifische Produkte anzeigen :

In Vitro

Treatment with GB1107 (0-1 μM) increases tumor M1 macrophage polarization and CD8+ T cell infiltration in LLC cells by flow cytometric analysis. GB1107 potentiates the effects of a PD-L1 immune checkpoint inhibitor to increase expression of cytotoxic (IFN-γ, granzyme B, perforin-1, Fas ligand) and apoptotic (cleaved caspase-3) effector molecules^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

GB1107 (10 mg/kg, p.o., once daily from day 18-30 post implantation) treatment results in significantly reduced tumor growth and final tumor weights^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

CD-1 nude female mice received 3x10⁶ human lung adenocarcinoma cells (A549)^[1].
Dosage:

10 mg/kg
Administration:

Oral once daily from day 18-30 post implantation.
Result:

Resulted in significantly reduced tumor growth and final tumor weights.

Chemical Information

CAS. Nr. 1978336-61-6
Appearance Solid
Molecular Weight 522.32
Formel C₂₀H₁₆Cl₂F₃N₃O₄S
Color White to off-white
SMILES

O[C@H]([C@@H](N1N=NC(C2=CC(F)=C(F)C(F)=C2)=C1)[C@H]([C@@H](CO)O3)O)[C@H]3SC4=CC=C(Cl)C(Cl)=C4
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

-20°C, stored under nitrogen

* In solvent : -80°C, 2 years; -20°C, 1 year (stored under nitrogen)

Publications (20)

All Histological Imaging/StainingIFIn Vivo Efficacy StudyCell Migration/Invasion Assay

Sort by:

Journal Impact Factor

Cell Res

Multiple cancer cell types release LIF and Gal3 to hijack neural signals. [Abstract]

2024 May;34(5):345-354. PMID: 38467743
Nat Commun

Galectin-3-integrin α5β1 phase separation disrupted by advanced glycation end-products impairs diabetic wound healing in rodents. [Abstract]

2025 Aug 7;16(1):7287. PMID: 40775187

GB1107 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 7;16(1):7287. [Abstract]

Eight-week-old female C57BL/6 J mice were fed with a chow diet. Full-thickness skin wounds were created and i.c. injected with Gal-3 inhibitor (GB1107, 133 μM, 100 µL/mouse) or solvent control (Veh). Picrosirius red staining in healed wound.

GB1107 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 7;16(1):7287. [Abstract]

Eight-week-old female C57BL/6 J mice were fed with a chow diet. Full-thickness skin wounds were created and i.c. injected with Gal-3 inhibitor (GB1107, 133 μM, 100 µL/mouse) or solvent control (Veh). CD31 staining in healed wound.
Cell Rep Med

Macrophage-coated tumor cluster aggravates hepatoma invasion and immunotherapy resistance via generating local immune deprivation. [Abstract]

2024 May 21;5(5):101505. PMID: 38614095

GB1107 purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 May 21;5(5):101505. [Abstract]

mIF imaging depicting the MCTC structure and distribution of CD8⁺ T cells (left), along with statistical analysis of the MCTC count (right), in C57 mice with subcutaneously implanted Hepa1-6^NC and Hepa1-6^M2Bphi tumors both with and without GB1107 (10 mg/kg, p.o.) treatment.

GB1107 purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 May 21;5(5):101505. [Abstract]

Overview of the tumor mass (left) and tumor growth curves (right) in the subcutaneously implanted tumors of the above groups. GB1107 (10 mg/kg, p.o.) reduced tumor burden and metastasis.

GB1107 purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 May 21;5(5):101505. [Abstract]

Supplemented with 1 μM GB1107, a migration assay was performed to quantify the number of macrophages that migrated when cocultured with tumor cells treated as described above at 24 h.
Carbohydr Polym

Functional structural domain synthesis of anti-pancreatic carcinoma pectin-like polysaccharide RN1. [Abstract]

2024 Mar 1:327:121668. PMID: 38171659
Research (Wash D C)

Single-Cell RNA Transcriptomics and Multi-omics Analyses Reveal the Clinical Effects of Acupuncture on Methadone Reduction. [Abstract]

2025 Jun 24:8:0741. PMID: 40556944
Cell Death Dis

Trajectory modeling of endothelial-to-mesenchymal transition reveals galectin-3 as a mediator in pulmonary fibrosis. [Abstract]

2021 Mar 26;12(4):327. PMID: 33771973
Int J Biol Sci

The KLF4/Galectin-3 cascade is a key determinant of tubular cell death and acute kidney injury. [Abstract]

2025 Sep 20;21(13):5802-5820. PMID: 41079936
Phytomedicine

Isoquercitrin attenuates the progression of non-alcoholic steatohepatitis in mice by modulating galectin-3-mediated insulin resistance and lipid metabolism. [Abstract]

2024 Jan:123:155188. PMID: 38056146
Commun Biol

TIM-3 on myeloid cells promotes pulmonary inflammation through increased production of galectin-3. [Abstract]

2024 Sep 5;7(1):1090. PMID: 39237613
Biochim Biophys Acta Mol Basis Dis

Methylglyoxal induces endothelial cell apoptosis and coronary microvascular dysfunction through regulating AR-cPLA2 signaling. [Abstract]

2024 Jul 25:167437. PMID: 39067539
Cancers (Basel)

Use of Glycoproteins-Prostate-Specific Membrane Antigen and Galectin-3 as Primary Tumor Markers and Therapeutic Targets in the Management of Metastatic Prostate Cancer. [Abstract]

2022 May 30;14(11):2704. PMID: 35681683
Mol Pain

Preoperative reactive oxygen species exacerbate postoperative hyperalgesia by aggravating neuroinflammation through galectin-3. [Abstract]

2025 Jun 13:17448069251353026. PMID: 40511781
FEBS Open Bio

Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer. [Abstract]

2021 Mar;11(3):911-920. PMID: 33455075
Thorac Cancer

Galectin-3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2-positive breast cancer cells. [Abstract]

2022 Jul;13(13):1961-1973. PMID: 35599381
Biochem Biophys Res Commun

Raman spectroscopic modality to examine therapeutic efficacy of Galectin-3 inhibitor in prostate cancer. [Abstract]

2025 Apr 9:757:151646. PMID: 40107110
Int J Endocrinol

Galectin-3 Inhibitors Suppress Anoikis Resistance and Invasive Capacity in Thyroid Cancer Cells. [Abstract]

2021 May 7:2021:5583491. PMID: 34035807
Oncol Lett

Inhibition of cancer cell‑platelet adhesion as a promising therapeutic target for preventing peritoneal dissemination of gastric cancer. [Abstract]

2023 Nov 1;26(6):538. PMID: 38020309
Res Sq

2026 Jun 2.
University of Indianapolis

2025.
Research Square Preprint

2024 Jan 9.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (95.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9145 mL

9.5727 mL

19.1453 mL

5 mM

0.3829 mL

1.9145 mL

3.8291 mL

10 mM

0.1915 mL

0.9573 mL

1.9145 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (stored under nitrogen). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: 2.5 mg/mL (4.79 mM); Suspended solution; Need ultrasonic

Protocol 5

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.79 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Vuong L, et al. An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade. Cancer Res. 2019 Jan 23. pii: canres.2244.2018. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9145 mL	9.5727 mL	19.1454 mL	47.8634 mL
	5 mM	0.3829 mL	1.9145 mL	3.8291 mL	9.5727 mL
	10 mM	0.1915 mL	0.9573 mL	1.9145 mL	4.7863 mL
	15 mM	0.1276 mL	0.6382 mL	1.2764 mL	3.1909 mL
	20 mM	0.0957 mL	0.4786 mL	0.9573 mL	2.3932 mL
	25 mM	0.0766 mL	0.3829 mL	0.7658 mL	1.9145 mL
	30 mM	0.0638 mL	0.3191 mL	0.6382 mL	1.5954 mL
	40 mM	0.0479 mL	0.2393 mL	0.4786 mL	1.1966 mL
	50 mM	0.0383 mL	0.1915 mL	0.3829 mL	0.9573 mL
	60 mM	0.0319 mL	0.1595 mL	0.3191 mL	0.7977 mL
	80 mM	0.0239 mL	0.1197 mL	0.2393 mL	0.5983 mL

Keywords

GB1107

20 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

GB1107

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Targeted Diversity Library

Anti-Pulmonary Fibrosis Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) GB1107

Alle Galectin Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (20)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

GB1107

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Targeted Diversity Library

Anti-Pulmonary Fibrosis Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) GB1107

Alle Galectin Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (20)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

GB1107 Related Classifications

HY-114409 Related Classifications